Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALPL | P05186 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370336 | 0.77 | TDP1 (0.46) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL17372395 | 0.76 | RXFP1 (0.50) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL7661207 | 0.73 | RXFP1 (0.42) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL8283565 | 0.71 | RXFP1 (0.41) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL4325559 | 0.70 | CYP2C19 (0.45) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL1078880 | 0.70 | PKN1 (0.47) | ALDH1A1HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL7671814 | 0.70 | RXFP1 (0.40) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL7670474 | 0.69 | RXFP1 (0.39) | RXFP1TP53THRBALDH1A1HTT | |
| SCHEMBL4422412 | 0.68 | ALDH1A1 (0.49) | RXFP1TP53THRBALDH1A1HPGD | |
| SCHEMBL17371875 | 0.68 | CDC7 (0.65) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-9162981-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162981-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2550263-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | The Johns Hopkins University (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | RXFP1 4435/4885TP53 3810/4885THRB 4059/4885 |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | CLN6, PSEN2, CHAT | RXFP1 4435/4885TP53 3810/4885THRB 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.